GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Margin of Safety % (DCF Earnings Based)

Nephros (Nephros) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nephros Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nephros's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.


Competitive Comparison of Nephros's Margin of Safety % (DCF Earnings Based)

For the Medical Instruments & Supplies subindustry, Nephros's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros's Margin of Safety % (DCF Earnings Based) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nephros's Margin of Safety % (DCF Earnings Based) falls into.



Nephros Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Nephros's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros (Nephros) Business Description

Industry
Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.
Executives
Banks Robert R. Jr. director, officer: President and CEO C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel officer: Chief Financial Officer 320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo officer: Chief Marketing Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor officer: Chief Financial Officer 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp director, 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino officer: Chief Financial Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans director, officer: President and CEO C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830

Nephros (Nephros) Headlines

From GuruFocus

Nephros Unveils New Branding and Website

By GuruFocusNews GuruFocusNews 04-26-2022

Nephros Announces Results for Quarter Ended March 31, 2023

By sperokesalga sperokesalga 05-10-2023

Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022

By Stock market mentor Stock market mentor 01-11-2023

Nephros Announces Results for Quarter Ended June 30, 2022

By PurpleRose PurpleRose 08-10-2022

Nephros Announces CEO Retirement and Succession Plan

By sperokesalga sperokesalga 05-08-2023

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 07-06-2022

Nephros and Donastar Announce Strategic Partnership

By sperokesalga sperokesalga 03-01-2023